HR 4278 United States House · 117th Congress

To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.

Summary
This bill requires the Government Accountability Office to study and report on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers.
Bill status in committee 1 of 4 stages cleared
Introduction
Jun 2021
Committee Review
Floor Vote
President
Introduced Jun 30, 2021 Last action Jul 1, 2021
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
3
Key actions
0
Committee
2
Jul 1, 2021
Committee
Referred to the Subcommittee on Health.
lower
Jun 30, 2021
Committee
Referred to the House Committee on Energy and Commerce.
lower
Jun 30, 2021
Introduced
Introduced in House
lower
1 primary · 1 co-sponsor

Sponsors